INSP Inspire Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1609550 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.2%
TTM net income YoY126.0%
TTM EPS YoY129.5%
Revenue 3-yr CAGR15.6%
Net income 3-yr CAGR—
Margins
Gross margin86.2%
Operating margin1.8%
Net margin11.4%
FCF margin11.1%
EBITDA margin3.9%
Returns
ROE13.5%
ROA11.4%
ROIC (approx.)2.6%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio6.45x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $206.69M | $200.58M | $204.58M | $269.08M | $224.50M | $217.09M | $201.32M | $239.72M |
| Cost of revenue | $28.84M | $29.12M | $27.67M | $36.07M | $31.77M | $34.67M | $30.71M | $35.99M |
| Gross profit | $177.86M | $171.46M | $176.91M | $233.01M | $192.73M | $182.41M | $170.61M | $203.73M |
| R&D expense | $22.18M | $24.70M | $25.83M | $24.94M | $24.21M | $26.21M | $27.80M | $30.34M |
| SG&A expense | $184.40M | $147.28M | $152.20M | $161.95M | $158.87M | $159.52M | $144.29M | $141.51M |
| Operating income | -$28.72M | -$514,000 | -$1.12M | $46.11M | $9.64M | -$3.32M | -$1.49M | $31.88M |
| Interest expense | — | — | — | $122,000 | $11,000 | $4,000 | — | $22,000 |
| Pretax income | -$25.01M | $3.12M | $2.40M | $50.32M | $13.55M | -$2.33M | $4.16M | $36.64M |
| Income tax | -$616,000 | $2.80M | $13.69M | -$85.77M | $3.62M | $1.26M | $1.17M | $1.41M |
| Net income | -$24.39M | $314,000 | -$11.29M | $136.09M | $9.93M | -$3.59M | $2.99M | $35.22M |
| EBITDA | -$23.62M | $4.09M | $3.99M | $49.93M | $13.34M | $84,000 | $1.56M | $34.36M |
| EPS (basic) | -0.84 | 0.01 | -0.39 | — | 0.34 | -0.12 | 0.10 | — |
| EPS (diluted) | -0.84 | 0.01 | -0.39 | — | 0.34 | -0.12 | 0.10 | — |
| Weighted avg. shares (diluted) | 28.93M | 28.94M | 28.70M | — | 29.60M | 29.51M | 30.31M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $190.80M | $127.76M | $98.93M | $104.81M | $112.84M | $106.93M | $53.88M | $150.15M |
| Short-term investments | $137.17M | $192.92M | $184.90M | $203.46M | $209.75M | $193.97M | $315.31M | $295.40M |
| Receivables | $104.71M | $103.34M | $105.09M | $119.69M | $107.99M | $137.69M | $92.63M | $93.07M |
| Inventory | $178.96M | $170.45M | $166.24M | $145.29M | $141.78M | $121.63M | $99.73M | $80.12M |
| Current assets | $627.62M | $608.67M | $566.82M | $583.65M | $586.49M | $573.19M | $571.68M | $630.81M |
| PP&E, net | $85.64M | $104.33M | $100.69M | $97.87M | $91.51M | $85.27M | $77.17M | $71.92M |
| Total assets | $953.03M | $925.99M | $911.38M | $907.32M | $807.72M | $802.19M | $730.81M | $808.38M |
| Current liabilities | $97.34M | $71.18M | $89.42M | $96.06M | $110.84M | $93.36M | $63.47M | $88.50M |
| Total liabilities | $126.08M | $100.41M | $119.04M | $126.16M | $141.26M | $124.38M | $95.07M | $118.69M |
| Shareholders' equity | $826.95M | $825.58M | $792.34M | $781.16M | $666.46M | $677.81M | $635.74M | $689.70M |
| Shares outstanding | 28.94M | 28.91M | 28.80M | 28.58M | 29.05M | 29.57M | 29.47M | 29.74M |
| Cash flow statement | ||||||||
| Operating cash flow | $46.43M | $23.23M | $12.85M | $52.47M | $68.53M | $2.68M | -$6.70M | $69.18M |
| Capital expenditure | $7.54M | $9.16M | $9.73M | $10.66M | $10.44M | $9.00M | $8.41M | $7.03M |
| Free cash flow | $38.88M | $14.07M | $3.12M | $41.81M | $58.09M | -$6.31M | -$15.11M | $62.15M |
| Investing cash flow | $17.05M | $3.55M | -$11.25M | -$11.92M | -$11.64M | $46.56M | -$1.55M | $3.76M |
| Financing cash flow | -$436,000 | $1.91M | -$7.48M | -$48.31M | -$51.08M | $3.70M | -$87.76M | -$70.14M |
| Depreciation & amortization | $5.10M | $4.60M | $5.11M | $3.82M | $3.70M | $3.40M | $3.04M | $2.48M |
| Stock-based compensation | $26.90M | $31.20M | $30.69M | $28.01M | $29.50M | $41.70M | $31.06M | $29.14M |
| Share buybacks | $0 | $0 | $0 | $50.01M | $50.00M | $0 | $75.01M | $75.00M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.